Monopar Therapeutics Inc
NASDAQ:MNPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Monopar Therapeutics Inc
NASDAQ:MNPR
|
US |
|
Ford Motor Co
NYSE:F
|
US |
|
A
|
ASFlow Co Ltd
KOSDAQ:159010
|
KR |
|
Sumitomo Mitsui Trust Holdings Inc
F:MIU
|
JP |
|
A
|
Alpha Professional Holdings Ltd
HKEX:948
|
HK |
|
S
|
Singapore Airlines Ltd
OTC:SINGF
|
SG |
|
P
|
Paramount Global
NASDAQ:PARAA
|
US |
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
US |
|
Prevas AB
STO:PREV B
|
SE |
|
Guardian Capital Group Ltd
TSX:GCG
|
CA |
|
Insigma Technology Co Ltd
SSE:600797
|
CN |
Monopar Therapeutics Inc
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Wilmette, Illinois and currently employs 9 full-time employees. The company went IPO on 2019-12-19. The firm is primarily focused on developing therapeutics designed for cancer patients. Its product pipeline includes Validive, camsirubicin, MNPR-101, and MNPR-202. The Validive is a first-in-class mucoadhesive buccal tablet for the prevention of radiation induced severe oral mucositis (SOM) in oropharyngeal cancer patients. Its camsirubicin is a clinical stage topoisomerase II-alpha selective novel analog of doxorubicin engineered specifically to retain anticancer activity while minimizing toxic effects on the heart. Its MNPR-101 is a humanized monoclonal antibody designed to bind a specific cell surface receptor found on cancer cells, the urokinase plasminogen activator receptor (uPAR), and to interrupt several pathways required for tumor growth and progression. The MNPR-202 is an early stage camsirubicin analog for various cancers.
